Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Read the highlights for the 2026 World Alzheimer's Month campaign, from ADI member activities to key events and achievements from the wider community of advocates united under the theme of ‘The Earlier You Know, The More You Can Do: A Dementia Diagnosis Matters’.
ADI announces our new CEO, joining on 1 October 2026
hinese Pharmaceutical Company Green Valley announces their drug Oligomannate (GV-971) has been granted conditional approval for the treatment of "mild to moderate Alzheimer's disease".
This piece questioning how we see and understand dementia friendly communities, their role and how they may evolve was contributed to the World Alzheimer Report 2019 by Glenn Rees, former Chair of ADI, and Dr Linda Barclay, a Senior Lecturer in Philosophy at Monash University who specialises in disability and justice.
Biogen and Eisai have announced they will file for market approval for an investigational treatment for early Alzheimer’s disease.
Ahead of the G20 Health Ministers Meeting in Okayama, ADI’s Chief Executive Paola Barbarino and Noriyo Washizu of Alzheimer's Association Japan (AAJ) continue to work on progress made earlier in the year at the Osaka Summit.
Ahead of the G20 Health Ministers Meeting in Okayama, ADI Chief Executive Paola was interviewed by one of Japan's largest newspaper.
The Spanish Ministry of Health, Consumption and Social Welfare has announced that they have adopted a national dementia plan.
New Zealand's Dementia Declaration is the result of people affected by dementia getting together and identifying what they need to live well.
Results from the world’s largest survey reveals that stigma around dementia is preventing people from seeking the information, advice, support and medical help.